ProShares UltraShort NASDAQ Biotechnology
6 hedge funds and large institutions have $992K invested in ProShares UltraShort NASDAQ Biotechnology in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1% more capital invested
Capital invested by funds: $984K → $992K (+$7.94K)
0.61% more ownership
Funds ownership: 9.45% → 10.06% (+0.61%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
25% less funds holding
Funds holding: 8 → 6 (-2)
85% less call options, than puts
Call options by funds: $4K | Put options by funds: $27K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$43K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$38.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$114K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$22.8K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $501K | +$43K | +1,021 | +10% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $259K | -$114K | -2,711 | -32% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $227K | +$38.9K | +923 | +22% |
|
4
Morgan Stanley
New York
| $2.71K | – | – | – |
|
5
Citigroup
New York
| $1.91K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $134 | -$22.8K | -542 | -99% |
|
|
7
Simplex Trading
Chicago,
Illinois
| – | -$6K | -164 | Closed |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.04K | -25 | Closed |
|
BIS Hedge Fund Activity: Q3 2023 in Review
6 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2023, worth a combined $992K — up 0.81% from $984K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, adding an estimated $43K. The largest seller was Susquehanna International Group, cutting an estimated $114K.
- 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2023, down from 8 in Q2 2023.
- Funds reported $992K of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2023, up 0.81% quarter-over-quarter.
- 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2023 was Citadel Advisors, an estimated $43K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2023 was Susquehanna International Group, an estimated $114K sold.
Based on aggregated 13F filings for Q3 2023.